| scholarly article | Q13442814 |
| P2093 | author name string | Wang D | |
| Cui L | |||
| Goldring SR | |||
| Yuan F | |||
| Quan LD | |||
| P2860 | cites work | Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy | Q22000845 |
| Modeling human arthritic diseases in nonhuman primates. | Q24810445 | ||
| A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs | Q28285226 | ||
| Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment | Q30318833 | ||
| Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat ad | Q73574475 | ||
| The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats | Q73734063 | ||
| Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes | Q73964545 | ||
| Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis | Q74242371 | ||
| Anti-inflammatory actions of glucocorticoids: molecular mechanisms | Q77686959 | ||
| THE MECHANISM OF HYPOALBUMINEMIA IN RHEUMATOID ARTHRITIS | Q78409445 | ||
| Biochemical confirmation of collapse due to adrenal failure | Q79012611 | ||
| The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats | Q80332159 | ||
| Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation | Q82360990 | ||
| Liposomal targeting of glucocorticoids to the inflamed synovium inhibits cartilage matrix destruction during murine antigen-induced arthritis | Q83554311 | ||
| Kinetic analysis of in vitro and in vivo release of prednisolone from the conjugate of glycol-chitosan and succinyl-prednisolone | Q83598500 | ||
| The bone, the joints and the Balm of Gilead | Q84619640 | ||
| Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis | Q84894424 | ||
| Permeability of Rheumatoid and Normal Human Synovium to Specific Plasma Proteins | Q71061671 | ||
| Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity | Q71221698 | ||
| Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice | Q71381902 | ||
| Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice | Q71386257 | ||
| Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis | Q71526058 | ||
| Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers--potential hapten or drug carriers | Q71793858 | ||
| Ibuprofen levels in serum and synovial fluid | Q72024431 | ||
| Upper limb lymphedema associated with polyarthritis of rheumatoid type | Q72731688 | ||
| Tissue and intracellular pH in normal periarticular soft tissue and during different phases of antigen induced arthritis in the rat | Q73010743 | ||
| Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis | Q73028001 | ||
| Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs | Q73212684 | ||
| Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model | Q30495832 | ||
| Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors | Q30702065 | ||
| Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis | Q30729184 | ||
| Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis | Q31139905 | ||
| Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society | Q33328546 | ||
| Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma | Q33371197 | ||
| Albumin metabolism in rheumatoid arthritis | Q33567806 | ||
| Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis | Q33606922 | ||
| In vivo efficacy of dendrimer-methylprednisolone conjugate formulation for the treatment of lung inflammation. | Q33643952 | ||
| Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats | Q33847787 | ||
| Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis | Q33870942 | ||
| HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action | Q33935270 | ||
| RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. | Q34062177 | ||
| Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis | Q34252148 | ||
| The epidemiology of rheumatoid arthritis | Q34275961 | ||
| Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy | Q34497135 | ||
| Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. | Q34565264 | ||
| Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. | Q34650477 | ||
| Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent | Q35088842 | ||
| Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates | Q35141592 | ||
| Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered | Q35489447 | ||
| Angiogenesis as a target in rheumatoid arthritis | Q35553507 | ||
| Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis | Q35553944 | ||
| Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo | Q35554251 | ||
| Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. | Q35769042 | ||
| Activity of type IV collagenases in benign and malignant breast disease | Q35976755 | ||
| Matrix metalloproteinases: role in arthritis | Q36251020 | ||
| Dampening inflammation | Q36348734 | ||
| Increased lymphangiogenesis in joints of mice with inflammatory arthritis | Q36465469 | ||
| Synthesis and in vitro characterization of novel dextran-methylprednisolone conjugates with peptide linkers: effects of linker length on hydrolytic and enzymatic release of methylprednisolone and its peptidyl intermediates. | Q36731983 | ||
| The Development of Novel Therapies for Rheumatoid Arthritis | Q36801049 | ||
| Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. | Q36810173 | ||
| Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists | Q36881025 | ||
| Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis | Q36994094 | ||
| Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles | Q37201079 | ||
| Hydrogel nanoparticles in drug delivery | Q37288965 | ||
| Dendrimers as versatile platform in drug delivery applications | Q37314393 | ||
| PEG conjugates in clinical development or use as anticancer agents: an overview | Q37578051 | ||
| Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. | Q37580085 | ||
| Immunogenicity and immunomodulatory properties of HPMA-based polymers | Q37633073 | ||
| Liposomal drug formulations in the treatment of rheumatoid arthritis | Q37884040 | ||
| The widening mortality gap between rheumatoid arthritis patients and the general population | Q38459919 | ||
| Intrinsically fluorescent PAMAM dendrimer as gene carrier and nanoprobe for nucleic acids delivery: bioimaging and transfection study | Q39452264 | ||
| Development of a novel polyethylene glycol-corticosteroid-conjugate with an acid-cleavable linker | Q39672742 | ||
| PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma | Q39796127 | ||
| Effects of branching architecture and linker on the activity of hyperbranched polymer-drug conjugates | Q39858988 | ||
| Controlled biodegradability of polymers — a key to drug delivery systems | Q40179445 | ||
| Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers. | Q40383123 | ||
| Super pH-sensitive multifunctional polymeric micelle | Q40442115 | ||
| Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. | Q40533473 | ||
| A multitude of kinases--which are the best targets in treating rheumatoid arthritis? | Q40840109 | ||
| Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia | Q42389455 | ||
| Rheumatoid arthritis in a mouse? | Q42572794 | ||
| Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis | Q43096548 | ||
| Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate | Q43740406 | ||
| Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry | Q43943205 | ||
| Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. | Q43959853 | ||
| A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies | Q44265675 | ||
| The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. | Q45155824 | ||
| Ibuprofen kinetics in plasma and synovial fluid of arthritic patients | Q45169483 | ||
| Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis | Q46356716 | ||
| Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis | Q46648038 | ||
| Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy | Q46702569 | ||
| Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates. | Q46978854 | ||
| Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. | Q47189752 | ||
| Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma | Q48241087 | ||
| Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis | Q48412481 | ||
| Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids | Q49035009 | ||
| Upper limb lymphatic function in inflammatory arthritis | Q49185577 | ||
| The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing | Q52575850 | ||
| Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. | Q53350997 | ||
| Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. | Q53381162 | ||
| Synovial pH in rheumatoid knee-joints. I. The effect of synovectomy. | Q53811497 | ||
| Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. | Q54140227 | ||
| Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. | Q54425576 | ||
| Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis | Q60541955 | ||
| Expression and activity of MMPS and their regulators in ovarian cancer | Q61819259 | ||
| Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression | Q68239605 | ||
| New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood | Q68508326 | ||
| Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure | Q68827896 | ||
| Risk of infectious complications in patients taking glucocorticosteroids | Q69561570 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | macromolecule | Q178593 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 1205-19 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | Development of macromolecular prodrug for rheumatoid arthritis | |
| P478 | volume | 64 |
| Q37672324 | Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-α siRNA in Chronic Inflammation Sites |
| Q59101195 | Application of liposomes in treatment of rheumatoid arthritis: quo vadis |
| Q39254173 | Biodistribution of Fracture-Targeted GSK3β Inhibitor-Loaded Micelles for Improved Fracture Healing |
| Q92261626 | Ca2+ signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats |
| Q40975743 | Celastrol inhibits inflammatory stimuli-induced neutrophil extracellular trap formation |
| Q91828114 | Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis |
| Q51748839 | Development of Controlled Drug Delivery Systems for Bone Fracture-Targeted Therapeutic Delivery: A Review. |
| Q57170627 | Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis |
| Q92574594 | Diclofenac Prodrugs for Intra-articular Depot Injectables: In Vitro Hydrolysis and Species Variation |
| Q42220990 | Early diagnosis of orthopedic implant failure using macromolecular imaging agents |
| Q36088192 | Effect of dexamethasone prodrug on inflamed temporomandibular joints in juvenile rats |
| Q36940281 | Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats |
| Q64245283 | Enhanced Therapeutic Effect of RGD-Modified Polymeric Micelles Loaded With Low-Dose Methotrexate and Nimesulide on Rheumatoid Arthritis |
| Q47731245 | Enrichment of malondialdehyde-acetaldehyde antibody in the rheumatoid arthritis joint |
| Q90513852 | Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model |
| Q41550801 | Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis. |
| Q51841138 | Formulation and evaluation of poly(lactic-co-glycolic acid) microspheres loaded with an altered collagen type II peptide for the treatment of rheumatoid arthritis. |
| Q47142933 | Fracture-Targeted Delivery of β-Catenin Agonists via Peptide-Functionalized Nanoparticles Augments Fracture Healing |
| Q90058555 | Glucocorticoids delivered by inorganic-organic hybrid nanoparticles mitigate acute graft-versus-host disease and sustain graft-versus-leukemia activity |
| Q38694388 | HPMA-Copolymer Nanocarrier Targets Tumor-Associated Macrophages in Primary and Metastatic Breast Cancer. |
| Q92317796 | LncRNA HOTAIR-mediated Wnt/β-catenin network modeling to predict and validate therapeutic targets for cartilage damage |
| Q37624988 | Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects |
| Q34079574 | Macromolecular therapeutics |
| Q89386407 | Micelle-Forming Dexamethasone Prodrug Attenuates Nephritis in Lupus-Prone Mice without Apparent Glucocorticoid Side Effects |
| Q37627094 | Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes |
| Q36585653 | Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis |
| Q90746319 | PET Imaging of Liposomal Glucocorticoids using 89Zr-oxine: Theranostic Applications in Inflammatory Arthritis |
| Q48361589 | Pharmacokinetic and Biodistribution Studies of HPMA Copolymer Conjugates in an Aseptic Implant Loosening Mouse Model |
| Q27002505 | Polymer-drug conjugates: origins, progress to date and future directions |
| Q26851258 | Progress in intra-articular therapy |
| Q38669113 | Recent advances in nanomedicines for the treatment of rheumatoid arthritis |
| Q89621507 | Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis |
| Q35042849 | Simvastatin prodrug micelles target fracture and improve healing |
| Q37562070 | TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis |
| Q87999519 | Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy |
| Q38264691 | Targeted delivery systems for biological therapies of inflammatory diseases |
| Q35951743 | Targeting polymer therapeutics to bone |
| Q41760506 | The Evaluation of Therapeutic Efficacy and Safety Profile of Simvastatin Prodrug Micelles in a Closed Fracture Mouse Model |
| Q36403152 | The Evaluation of the Therapeutic Efficacy and Side Effects of a Macromolecular Dexamethasone Prodrug in the Collagen-Induced Arthritis Mouse Model |
| Q28548580 | Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases |
Search more.